Funder
Ironwood Pharmaceuticals, Incorporated
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Schumacher HR Jr, Becker MA, Wortmann RL, MacDonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540–8.
2. So A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62:3064–76.
3. Timilsina S, Brittan K, O'Dell J, Brophy M, Davis-Karim A, Henrie A, et al. Design and rationale for the veterans affairs “cooperative study program 594 comparative effectiveness in gout: allopurinol vs. febuxostat” trial. Contemp Clin Trials. 2018;68:102–8.
4. Schumacher HR Jr, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, et al. Rilonacept (Interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64:876–84.
5. Saag K, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, et al. FRI0320 Lesinurad, a selective URIC acid reabsorption inhibitor, in combination with allopurinol: results from a phase III study in gout patients having an inadequate response to standard of care (clear 1). Ann Rheum Dis. 2015;74:540.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献